<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096874</url>
  </required_header>
  <id_info>
    <org_study_id>RP 1310</org_study_id>
    <nct_id>NCT02096874</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema</brief_title>
  <official_title>The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Khaled Eye Specialist Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Khaled Eye Specialist Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ultra-wide field fluorescein angiography can detect the response of anti VGEF therapy such as
      Avastin on retinal ischemia in the setting of diabetic macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major causes of vision loss in diabetic retinopathy are diabetic macular edema (DME)
      characterized by thickening of the macula due to abnormal leakage of the retinal vasculature.
      Ischaemic changes and microvascular pathologies have long been hypothesized to play a role in
      the development of DME. In diabetic retinopathy, ischaemia stimulates the production of
      vascular endothelial growth factor (VEGF), which can lead to the breakdown of blood-retinal
      barriers, and may cause DME through an increase in retinal vessel permeability. DME is best
      evaluated by optical coherence tomography (OCT) while retinal ischemia is determined by
      Fluorescein angiography. With the avaiability of ultra wide field fluorescein angiography,
      the investigators can now accurately measure the degree of ischemia in peripheral retina.
      Thus, this study will provide us data on the degree of retinal ischemia in nonproliferative
      diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) cases as well as the
      measurable change that occurs in retinal ischemia after intra vitreal injection of
      bevacizumab.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral retinal ischemia</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in peripheral retinal ischemia after intravitreal bevacizumab injection in non proliferative diabetic retinopathy and proliferative diabetic retinopathy.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-proliferative Diabetic Retinopathy</condition>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each study subject will recieve Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diabetic patients at age &gt;18year with DME

          2. Scheduled for Avastin therapy

          3. Adequate media to obtain OCT and UWFA

        Exclusion Criteria:

          1. Macular pathology of any etiology

          2. Preexisting systemic disease causing retinal ischemia

          3. Previous laser or anti-VEGF treatment in past 3 months

          4. Previous retina surgery in past 2 months

          5. Allergy to fluorescein dye

          6. Psychiatric disorder, Alzheimer disease and Dementia or any other disorder precluding
             follow-up or continuation of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saba al Rashaed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Khaled Eye Specialist Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ovais M Shaikh, MD</last_name>
    <phone>(966) 4821234</phone>
    <phone_ext>1139</phone_ext>
    <email>mshaikh@kkesh.med.sa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdul Rahman Hommadi</last_name>
    <phone>(966)4821234</phone>
    <phone_ext>3737</phone_ext>
    <email>ahommadi@kkesh.med.sa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King Khaled Eye Specialist Hospital</name>
      <address>
        <city>Riyadh</city>
        <zip>11462</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Khaled Eye Specialist Hospital</investigator_affiliation>
    <investigator_full_name>Saba al Rashaed</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Peripheral retinal ischemia</keyword>
  <keyword>ultra wide field fluorescein angiography</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

